EXHIBIT INDEX. Exhibit 2.1 – Certificate of Formation for RSE Collection, LLC (1) Exhibit 2.2 – Fifth Amended and Restated Limited Liability Company Agreement of RSE Collection, LLC (4) Exhibit 2.3 – Certificate of Formation for RSE Collection Manager, LLC (3) Exhibit 2.4 – Limited Liability Company Agreement of RSE Collection Manager, LLC (4) Exhibit 3.1 – Amended and Restated Standard Form of Series Designation (3) Exhibit 4.1 – Standard Form of Subscription Agreement (10) Exhibit 6.1 – Amended and Restated Standard Form of Asset Management Agreement (4) Exhibit 6.2 – Amended and Restated Broker of Record Agreement (5) Exhibit 6.3 – Amended and Restated Upper90 Secured Demand Promissory Term Note (2) Exhibit 6.4 – Upper90 Credit and Guaranty Agreement (3) Exhibit 6.5 – Standard Form Bill of Sale (3) Exhibit 6.6 – Standard Form Purchase Agreement (4) Exhibit 6.7 – NCPS PPEX ATS Company Agreement (4) Exhibit 6.8 – Executing Broker Secondary Market Transactions Engagement Letter (4) Exhibit 6.9 – Executing Broker Tools License Agreement (4) Exhibit 6.10 – Transfer Agent Agreement (5) Exhibit 6.11 – NCIT Software and Services License Agreement (6) Exhibit 6.12 – Form of Assignment and Assumption Agreement (7) Exhibit 6.13 – Standard Form #2 Purchase Agreement (8) Exhibit 6.14 – Standard Form Purchase Option Agreement (12) Exhibit 6.15 – Standard Form Consignment Agreement (12) Exhibit 6.16 – Purchase Agreement in respect of Series #BATMAN1 (12) Exhibit 6.17 – Form #2 of Assignment and Assumption Agreement (17) Exhibit 8.1 – Amended and Restated Subscription Escrow Agreement (10) Exhibit 8.2 – Amended and Restated Custody Agreement (5) Exhibit 11.1 – Consent of EisnerAmper LLP (17) Exhibit 12.1 – Opinion of Xxxxxxx, Xxxxxx & Xxxx, P.C. (17) Exhibit 13.1 – Testing the Waters Materials for Series #MACWORLD1 (9) Exhibit 13.2 – Testing the Waters Materials for Series #BONDWATCH (9) Exhibit 13.3 – Testing the Waters Materials for Series #95FF1 (10) Exhibit 13.4 – Testing the Waters Materials for Series #MAYC857 (11) Exhibit 13.5 – Testing the Waters Materials for Series #TREASURE (12) Exhibit 13.6 – Testing the Waters Materials for Series #57UNITAS (12) Exhibit 13.8 – Testing the Waters Materials for Series #PUNK2981 (12) Exhibit 13.9 – Testing the Waters Materials for Series #WOW2221 (12) Exhibit 13.10 – Testing the Waters Materials for Series #BAKC7820 (12) Exhibit 13.11 – Testing the Waters Materials for Series # BATMAN (12) Exhibit 13.12 – Testing the Waters Materials for Se...
EXHIBIT INDEX. Exhibit Description ------- ----------- 0.2 Description of the Subsidiary's Business 1.3 Subsidiary's Liabilities 2.1 Corporation's Warranty Exceptions 2.2 Subsidiary's Warranty Exceptions 2.2(a) List of Assets Owned or Leased by the Subsidiary and its Affiliates. 2.2(j) Subsidiary's Financial Statements 2.2(y) Subsidiary's Insurance Policies or Binders 2.3 Subscriber's Warranty Exceptions 2.3(c) Questionnaires 2.3(d) Regulation SB Disclosure Narrative 4.2(d) Investment Letter * * *
EXHIBIT INDEX. Exhibit A Assignment and Assumption Agreement Exhibit B Employment Agreement of P. Xxxxxxx Xxxxxxxx Exhibit C Form of Bankruptcy Court Orders ASSET PURCHASE AGREEMENT
EXHIBIT INDEX. Exhibit No. Exhibit Matter ----------- -------------- Exhibit A Owners' Businesses 1.1(1) Real Estate 1.1(2) Equipment and Furnishings 1.1(10) Intangible Property 1.2 Excluded Assets 1.3(1) Leased Property 1.3(2) Leased Equipment and Furnishings 1.3(8) Leased Intangible Property 1.4 Assumed Liabilities 3.3 Purchase Price Allocation 4.2 Subsidiaries 4.3 Consents 4.4 Financial Statements 4.5 Operations since September 30, 1996 4.6 Absence of Liabilities 4.7 Employment Discrimination 4.8(1) Licenses and Permits 4.9(1) Program Agreements 4.9(2) Statement of Deficiencies and Plan of Correction 4.11 Easements 4.12(1) Encumbrances 4.12(2) Permitted Exceptions 4.13 Leases and Contracts 4.14(2) Noncompliance with Environmental Law 4.14(3) Underground Storage Tanks 4.15 Appraisals, Mechanical and Structural Studies, etc. 4.16 Litigation 4.17 Employees 4.19 Insurance 4.20 Brokers, Finders or Consultants 4.21 Conflicts of Interest 4.23 Intellectual Property 4.25(1) Welfare Benefit Plans 4.25(2) Pension Benefit Plans 4.25(3) Unfunded Liabilities 4.27 Condition of Assets 4.31 Resident Agreements 4.33 Prepayments and Deposits 4.34 Occupancy Rates 6.1 Changes in Business or Assets 6.19 Employment of Certain Individuals 9.9 Form of Lease Agreement 9.10 Form of Consulting Agreement (Stevx Xxxxxx)
EXHIBIT INDEX. Exhibit A Escrow Agreement Exhibit B-1 Form of Founding Agreement Exhibit B-2 Form of Charter Exhibit C Company Participants’ Meeting Agenda Exhibit D Historical Financial Statements Exhibit F Form of Waiver Exhibit G-1 Form of Seller’s Certificate Exhibit G-2 Form of Purchaser’s Certificate Exhibit H List of Management Disclosure Schedule Exceptions to Warranties Concerning the Company PARTICIPATION INTEREST PURCHASE AGREEMENT This PARTICIPATION INTEREST PURCHASE AGREEMENT (the “Agreement”) entered into as of November 5, 2002, by and between Mobile TeleSystems OJSC, an open joint stock company organized under the laws of the Russian Federation (the “Purchaser”); Cetel B.V., a limited liability company established and acting under the laws of the Netherlands (the “Seller”); and Deutsche Telekom AG, a company organized under the laws of Germany (“DT”). The Purchaser, DT and the Seller are referred to collectively herein as the “Parties.”
EXHIBIT INDEX. Exhibit A: Combined Therapy Studies to be Conducted (as of Effective Date) Exhibit B: Press Release Exhibit C: Form of Study Plan Schedule 2.1(c) Study Site Territories EXHIBIT B Press Release Checkmate Pharmaceuticals Announces Clinical Collaboration with Bristol Xxxxx Squibb to Evaluate CMP-001 in Combination with Nivolumab CAMBRIDGE, Mass., December 8, 2020 – Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate Pharmaceuticals”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced it has entered into a clinical collaboration agreement with Bristol Xxxxx Squibb (NYSE: BMY) to evaluate the combination of Checkmate Pharmaceuticals’ CMP-001, a Toll-like receptor 9 (TLR9) agonist, and Bristol Xxxxx Squibb’s Opdivo® (nivolumab), a PD-1 blocking antibody. The companies will collaborate on two trials: (a) a single arm Phase 2 study of CMP-001 in combination with nivolumab in subjects with unresectable or metastatic melanoma that is refractory to PD-1 blockade as monotherapy or in combination with other therapies, and (b) a randomized Phase 2 study of first-line CMP-001 in combination with nivolumab compared to nivolumab monotherapy in subjects with unresectable or metastatic melanoma. For both trials, under the terms of the agreement, Checkmate Pharmaceuticals will be the sponsor and Bristol Xxxxx Squibb will supply nivolumab. “This collaboration between Checkmate Pharmaceuticals and Bristol Xxxxx Squibb underscores our mutual dedication to advancing the impact of immunotherapy for the benefit of patients living with melanoma and other types of cancer,” said Xxxxx Xxxxxxxx, President and Chief Executive Officer of Checkmate Pharmaceuticals. “We believe that CMP-001 in combination with Opdivo offers promise for patients and we are pleased to be working together with Bristol Xxxxx Squibb on this important pursuit.” Opdivo® is a registered trademark of Bristol Xxxxx Squibb. About Checkmate Pharmaceuticals Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate Pharmaceuticals’ product candidate, CMP-001, is an advanced generation TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body’s innate immune system to attack tumors in combination with other therapies. Information regarding Chec...
EXHIBIT INDEX. Exhibit No. Description
EXHIBIT INDEX. Exhibit A – Persons to Sign Support Agreements Exhibit B – Form of Support Agreement Exhibit C – Bank Merger Agreement Exhibit D – Form of Business Protection Agreement EXHIBIT A Persons to Sign Support Agreements Xxxxx X. Xxxxxxx Xxxx X. Xxxxxxx XXXXXX C LLC CANASI N LLC CANASI S LLC EXHIBIT B SUPPORT AGREEMENT This Support Agreement, dated as of December 18, 2015 (this “Agreement”), is made and entered into by and between Xxxxxxx Bancorp, Inc., a Maryland corporation (“Xxxxxxx”), and _________________ (the “Stockholder”), as a stockholder of Xxxxxxx.
EXHIBIT INDEX. 14 PART I ITEM 1 FINANCIAL STATEMENTS CELL THERAPEUTICS, INC. (A DEVELOPMENT STAGE COMPANY) CONSOLIDATED BALANCE SHEETS JUNE 30, 1997 DECEMBER 1996 31, ------------ ------------ ASSETS Current assets: Cash and cash equivalents........................ (UNAUDITED) $ 3,326,226 $ 5,483,515 Securities available-for-sale.................... 44,590,786 25,503,049 Collaboration agreement receivables.............. 2,547,487 --
EXHIBIT INDEX. Exhibit A Certificate of Designation Exhibit B Registration Rights Agreement Exhibit C Shareholder's Agreement
